Publication about Aortic Valve Stenosis in ATVB
March 12, 2020
Aortic Valve Stenosis – From Basic Mechanisms to Novel Therapeutic TargetsAortic valve stenosis (AVS) is the most common acquired heart valve disease in the western world. The morbidity and mortality associated with AVS is tremendous and the 2-year mortality rate is around 50%. A complex process of endothelial dysfunction, immune cell infiltration, myofibroblastic and osteoblastic differentiation and subsequently calcification leads to remodeling and thickening of the aortic valve cups. The changes results in valve obstruction. The underlying pathophysiology of calcification are still unclear and no pharmacotherapy has been established to prevent aortic valve calcification. This review summarizes the current knowledge of pathomechanisms involved in aortic valve calcification and points out novel treatment strategies.
|
Phases of calcific aortic valve disease (CAVD) Pathomechanisms of initiation and progression of CAVD can be seen as distinct disease phases: endothelial dysfunction and lipid deposition, inflammation, fibrosis, and calcification. © 2020 American Heart Association, Inc. |
|
Publication
Philip Roger Goody, Mohammed Rabiul Hosen, Dominik Christmann, Sven Thomas Niepmann, Andreas Zietzer, Matti Adam, Florian Bönner, Sebastian Zimmer, Georg Nickenig, Felix Jansen: Aortic Valve Stenosis – From Basic Mechanisms to Novel Therapeutic Targets; Arteriosclerosis, Thrombosis, and Vascular Biology 2020 Apr;40(4):885–900; DOI: 10.1161/ATVBAHA.119.313067
Correspondence
Philip Roger Goody, Heart Center Bonn, Department of Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany, E-mail Address: [Email protection active, please enable JavaScript.]
|
|
